These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 17085196)

  • 41. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions.
    Matsumoto M; Ohtsuki Y; Ochii K; Seike Y; Iseda N; Sasaki T; Okada Y; Kurabayashi A; Furihata M
    Oncol Rep; 2004 Nov; 12(5):967-71. PubMed ID: 15492779
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
    Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequent association of p53 gene mutation in invasive bladder cancer.
    Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
    Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. p53 gene mutation in recurrent superficial bladder cancer.
    Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
    J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
    Lindgren D; Frigyesi A; Gudjonsson S; Sjödahl G; Hallden C; Chebil G; Veerla S; Ryden T; Månsson W; Liedberg F; Höglund M
    Cancer Res; 2010 May; 70(9):3463-72. PubMed ID: 20406976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
    Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
    Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
    Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. p53 mutations and prognosis in bladder tumors.
    Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
    J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
    Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
    Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frequent FGFR3 mutations in urothelial papilloma.
    van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
    J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
    Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
    Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer.
    Pandith AA; Shah ZA; Siddiqi MA
    Urol Oncol; 2013 May; 31(4):398-406. PubMed ID: 20822928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.
    Sanchez-Carbayo M; Socci ND; Kirchoff T; Erill N; Offit K; Bochner BH; Cordon-Cardo C
    Clin Cancer Res; 2007 Jun; 13(11):3215-20. PubMed ID: 17545525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
    Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
    Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.